Cargando…
Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation
Licochalcone-A is a natural compound with anti-inflammatory properties. However, it possesses low water solubility, making its application for the treatment of ocular inflammation difficult. To overcome this drawback, biodegradable nanoparticles incorporating Licochalcone-A have been developed. Addi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874979/ https://www.ncbi.nlm.nih.gov/pubmed/35214019 http://dx.doi.org/10.3390/pharmaceutics14020285 |
_version_ | 1784657815731699712 |
---|---|
author | Galindo, Ruth Sánchez-López, Elena Gómara, María José Espina, Marta Ettcheto, Miren Cano, Amanda Haro, Isabel Camins, Antoni García, María Luisa |
author_facet | Galindo, Ruth Sánchez-López, Elena Gómara, María José Espina, Marta Ettcheto, Miren Cano, Amanda Haro, Isabel Camins, Antoni García, María Luisa |
author_sort | Galindo, Ruth |
collection | PubMed |
description | Licochalcone-A is a natural compound with anti-inflammatory properties. However, it possesses low water solubility, making its application for the treatment of ocular inflammation difficult. To overcome this drawback, biodegradable nanoparticles incorporating Licochalcone-A have been developed. Additionally, to avoid fast clearance and increase cellular internalization into the ocular tissues, PLGA nanoparticles have been functionalized using PEG and cell penetrating peptides (Tet-1 and B6). To optimize the formulations, a factorial design was carried out and short-term stability of the nanoparticles was studied. Moreover, morphology was also observed by transmission electron microcopy and in vitro drug release was carried out. Ocular tolerance of the formulations was ensured in vitro and in vivo and anti-inflammatory therapeutic efficacy was also assessed. Surface functionalized nanoparticles loading Licochalcone-A were developed with an average size below 200 nm, a positive surface charge, and a monodisperse population. The formulations were non-irritant and showed a prolonged Licochalcone-A release. Despite the fact that both Licochalcone-A Tet-1 and B6 functionalized nanoparticles demonstrated to be suitable for the treatment of ocular inflammation, B6 targeted nanoparticles provided greater therapeutic efficacy in in vivo assays. |
format | Online Article Text |
id | pubmed-8874979 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88749792022-02-26 Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation Galindo, Ruth Sánchez-López, Elena Gómara, María José Espina, Marta Ettcheto, Miren Cano, Amanda Haro, Isabel Camins, Antoni García, María Luisa Pharmaceutics Article Licochalcone-A is a natural compound with anti-inflammatory properties. However, it possesses low water solubility, making its application for the treatment of ocular inflammation difficult. To overcome this drawback, biodegradable nanoparticles incorporating Licochalcone-A have been developed. Additionally, to avoid fast clearance and increase cellular internalization into the ocular tissues, PLGA nanoparticles have been functionalized using PEG and cell penetrating peptides (Tet-1 and B6). To optimize the formulations, a factorial design was carried out and short-term stability of the nanoparticles was studied. Moreover, morphology was also observed by transmission electron microcopy and in vitro drug release was carried out. Ocular tolerance of the formulations was ensured in vitro and in vivo and anti-inflammatory therapeutic efficacy was also assessed. Surface functionalized nanoparticles loading Licochalcone-A were developed with an average size below 200 nm, a positive surface charge, and a monodisperse population. The formulations were non-irritant and showed a prolonged Licochalcone-A release. Despite the fact that both Licochalcone-A Tet-1 and B6 functionalized nanoparticles demonstrated to be suitable for the treatment of ocular inflammation, B6 targeted nanoparticles provided greater therapeutic efficacy in in vivo assays. MDPI 2022-01-26 /pmc/articles/PMC8874979/ /pubmed/35214019 http://dx.doi.org/10.3390/pharmaceutics14020285 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Galindo, Ruth Sánchez-López, Elena Gómara, María José Espina, Marta Ettcheto, Miren Cano, Amanda Haro, Isabel Camins, Antoni García, María Luisa Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation |
title | Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation |
title_full | Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation |
title_fullStr | Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation |
title_full_unstemmed | Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation |
title_short | Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation |
title_sort | development of peptide targeted plga-pegylated nanoparticles loading licochalcone-a for ocular inflammation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874979/ https://www.ncbi.nlm.nih.gov/pubmed/35214019 http://dx.doi.org/10.3390/pharmaceutics14020285 |
work_keys_str_mv | AT galindoruth developmentofpeptidetargetedplgapegylatednanoparticlesloadinglicochalconeaforocularinflammation AT sanchezlopezelena developmentofpeptidetargetedplgapegylatednanoparticlesloadinglicochalconeaforocularinflammation AT gomaramariajose developmentofpeptidetargetedplgapegylatednanoparticlesloadinglicochalconeaforocularinflammation AT espinamarta developmentofpeptidetargetedplgapegylatednanoparticlesloadinglicochalconeaforocularinflammation AT ettchetomiren developmentofpeptidetargetedplgapegylatednanoparticlesloadinglicochalconeaforocularinflammation AT canoamanda developmentofpeptidetargetedplgapegylatednanoparticlesloadinglicochalconeaforocularinflammation AT haroisabel developmentofpeptidetargetedplgapegylatednanoparticlesloadinglicochalconeaforocularinflammation AT caminsantoni developmentofpeptidetargetedplgapegylatednanoparticlesloadinglicochalconeaforocularinflammation AT garciamarialuisa developmentofpeptidetargetedplgapegylatednanoparticlesloadinglicochalconeaforocularinflammation |